• LAST PRICE
    0.1200
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.1200
  • Day Range
    ---
  • 52 Week Range
    Low 0.1200
    High 0.5550
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
Table Data Not Available
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesRGMP
Regnum Corp
2.8M
-3.0x
---
United StatesCNSP
CNS Pharmaceuticals Inc
2.9M
-6.0x
---
United StatesCFRX
ContraFect Corp
2.9M
0.0x
---
United StatesPTEO
Proteo Inc
3.0M
0.0x
---
United StatesXSNX
NovAccess Global Inc
3.0M
-1.5x
---
United StatesPHBI
Pharmagreen Biotech Inc
3.1M
-2.8x
---
As of 2023-02-09

Company Information

Regnum Corp. is a biopharmaceutical company. The Company is focused on late-stage commercial and clinical development programs. The Company is engaged in developing and commercializing therapeutics that treat rare and infectious diseases, specifically in populations that are neglected or face adherence challenges due to inconvenient dosing or delivery system, tolerability, or cost and accessibility of available therapeutic options. The Company's primary asset is the commercial rights to leronlimab (PRO 140) in all human immunodeficiency virus (HIV) indications within the United States. leronlimab is used as a platform drug for a variety of HIV indications. The target of leronlimab is the immunologic receptor C-C chemokine receptor type 5 (CCR5). Leronlimab prevents certain strains of HIV from using the CCR5 receptor as an entry gateway for healthy cells.

Contact Information

Headquarters
600 THIRD AVENUE, 10THNEW YORK, NY, United States 10016
Phone
917-647-1498
Fax
---

Executives

President, Chief Executive Officer, Director
Anne Kirby
Chief Financial Officer, Treasurer
Robert Stubblefield

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.8M
Revenue (TTM)
$0.00
Shares Outstanding
23.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.04
Book Value
$-0.02
P/E Ratio
-3.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.